Kenvue Inc. (FRA:J4D)
Germany · Delayed Price · Currency is EUR 19.28
-0.08 (-0.41%)
Last updated: Jul 29, 2025
Intra-Cellular Therapies Revenue
Kenvue had revenue of $3.74B USD in the quarter ending March 30, 2025, a decrease of -3.93%. This brings the company's revenue in the last twelve months to $15.30B, down -1.19% year-over-year. In the year 2024, Kenvue had annual revenue of $15.46B with 0.07% growth.
Revenue (ttm)
$15.30B
Revenue Growth
-1.19%
P/S Ratio
2.55
Revenue / Employee
$695.55K
Employees
22,000
Market Cap
35.98B
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 29, 2024 | 15.46B | 11.00M | 0.07% |
| Dec 31, 2023 | 15.44B | 494.00M | 3.30% |
| Jan 1, 2023 | 14.95B | -104.00M | -0.69% |
| Jan 2, 2022 | 15.05B | 587.00M | 4.06% |
| Jan 3, 2021 | 14.47B | 143.00M | 1.00% |
| Dec 29, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| SAP SE | 35.89B |
| Siemens Aktiengesellschaft | 77.82B |
| Deutsche Telekom AG | 120.25B |
| Allianz SE | 109.03B |
| Siemens Energy AG | 37.44B |
| Rheinmetall AG | 10.48B |
| Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 61.84B |
| Deutsche Bank Aktiengesellschaft | 30.07B |